Device Trial Radar · NCT02225392
Unravelling Targets of Therapy in Bronchial Thermoplasty in Severe Asthma
Last checked: Nov 20, 2026Latest source record: Dec 5, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
40
Actual
Start
Apr 2014
Primary completion
Dec 2019
Study completion Dec 2019
Sponsor
- Lead sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)Academic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- ZonMw: The Netherlands Organisation for Health Research and Development; The Netherlands Asthma Foundation; Boston Scientific Corporation
- First posted
- Aug 26, 2014
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Basic science
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Approximately 5% of asthma patients suffer from severe asthma that is characterized by frequent asthma exacerbations resulting in significant morbidity and excessive utilisation of health care resources. Therefore, there is a strong need for improved therapeutic strategies for these patients. Insight in the pathogenesis and molecular pathways active in severe asthma is crucial to reach this goal. Bronchial Thermoplasty (BT) is a novel, innovative device-based treatment of severe asthma that is based on local, radiofrequent energy delivery in larger airways during bronchoscopy. Hypothesis: BT-induced clinical improvement in severe asthma is a consequence of reduction in airway smooth muscle (ASM) mass and (contractile/immunomodulatory) function, inflammation, neural innervation and/or vascular integrity resulting in altered airway remodelling. BT target identification and severe asthma phenotyping are critical for improved patient selection for BT and fundamental to discover novel, specific signalling pathways active in severe asthma.
Conditions
- Asthma
- Bronchial Asthma
Interventions
Bronchial thermoplastyProcedure
Bronchial thermoplasty (BT) will be performed using the Alair system (Boston Scientific, USA). Patients will undergo 3 bronchoscopy procedures with BT at least 3 weeks apart. Treatment sessions are designed to address different lobes of the lung with the right lower lobe treated during the first bronchoscopy, the left lower lobe treated during the second bronchoscopy, and both the right and left upper lobes treated in the third and final bronchoscopy. The right middle lobe and proximal airways including RC2 are left untreated.
Alair system (Boston Scientific, USA)Device
The alair system consist of a controller and a bastket catheter.
Primary outcomes
What the sponsor says the trial is designed to measure.
- The change in airway smooth muscle (ASM) mass between immediate BT treated and the control group (N=20, randomized)Time frame: Baseline, week 25
Locations
3 sites in 2 countries. Site status is shown where the registry gives one.
University Medical Center Groningen
Groningen, Netherlands
Academisch Medisch Centrum
Amsterdam, North Holland, Netherlands
Royal Brompton Hospital
London, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.